These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 20169638)

  • 1. Heart attack warning issued.
    AIDS Patient Care STDS; 2010 Jan; 24(1):65-6. PubMed ID: 20169638
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women.
    Martorell C; Theroux E; Bermudez A; Garb J; Kronschnabel D; Oie K
    Pediatr Infect Dis J; 2010 Oct; 29(10):985. PubMed ID: 20859183
    [No Abstract]   [Full Text] [Related]  

  • 3. Four posters add to our knowledge of Lexiva.
    Proj Inf Perspect; 2008 Dec; (47):7-8. PubMed ID: 19227558
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
    Randell PA; Jackson AG; Boffito M; Back DJ; Tjia JF; Taylor J; Mandalia S; Moyle GJ
    Antivir Ther; 2010; 15(8):1125-32. PubMed ID: 21149919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment on: Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
    Lanzafame M; Lattuada E; Corsini F
    J Antimicrob Chemother; 2009 Jul; 64(1):215-6; author reply 216. PubMed ID: 19318364
    [No Abstract]   [Full Text] [Related]  

  • 7. Favourable use of non-boosted fosamprenavir in patients treated with warfarin.
    Honda H; Gatanaga H; Matsumura J; Kamimura M; Goto K; Tsukada K; Honda M; Teruya K; Kikuchi Y; Oka S
    Int J STD AIDS; 2009 Jun; 20(6):441. PubMed ID: 19451340
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA notifications. FDA approves new formulation of Lexiva.
    AIDS Alert; 2007 Aug; 22(8):90-1. PubMed ID: 17768778
    [No Abstract]   [Full Text] [Related]  

  • 9. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract]   [Full Text] [Related]  

  • 10. NEAT trial releases results.
    AIDS Patient Care STDS; 2002 Dec; 16(12):617. PubMed ID: 12881881
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term virus suppression. Expanding therapy options with protease inhibitor].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():68-9. PubMed ID: 16385882
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-HIV agents. Saquinavir with fosamprenavir.
    TreatmentUpdate; 2004; 16(3):9. PubMed ID: 17219609
    [No Abstract]   [Full Text] [Related]  

  • 15. [Maintaining independence. New protease inhibitor receives drug approval recommendation].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():84-5. PubMed ID: 15373062
    [No Abstract]   [Full Text] [Related]  

  • 16. [FPV plus SQV plus a mini-dose ritonavir. "Double boosting with compatible partners].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():92-3. PubMed ID: 15373070
    [No Abstract]   [Full Text] [Related]  

  • 17. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
    MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
    [No Abstract]   [Full Text] [Related]  

  • 18. Fosamprenavir: drug development for adherence.
    Hester EK; Chandler HV; Sims KM
    Ann Pharmacother; 2006; 40(7-8):1301-10. PubMed ID: 16757678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From amprenavir to GW433908.
    Gatell JM
    J HIV Ther; 2001 Nov; 6(4):95-9. PubMed ID: 11740410
    [No Abstract]   [Full Text] [Related]  

  • 20. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Pérez-Elias MJ; Sánchez-Conde M; Soriano V; Mallolas J; Luque I; Rodríguez-Alcántara F;
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.